Cholesterol and triglyceride concentrations following 12–18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor—PROMISE sub-study
In a population of youth and young adults with CF, TC and HDL-C were higher after 12-18 months of ETI, but differences in TC were attenuated with adjustment for BMI-Z. Prevalence of low HDL-C was high at both timepoints.
Authors
- Steven M. Rowe (ORCID: https://orcid.org/0000-0001-9045-0133)
- Sarah Jane Schwarzenberg (ORCID: https://orcid.org/0000-0001-5077-7625)
- Andrea Kelly (ORCID: https://orcid.org/0000-0003-1724-9868)
- Michael S. Stalvey (ORCID: https://orcid.org/0000-0003-4257-5710)
- Rosara Bass (ORCID: https://orcid.org/0000-0003-3290-7355)
- David P. Nichols (ORCID: https://orcid.org/0000-0001-8611-7960)
- Steven D. Freedman
- George M. Solomon (ORCID: https://orcid.org/0000-0002-2969-5518)
- Rachel Walega (ORCID: https://orcid.org/0000-0003-1170-6028)
Institutions
- Fairview Health Services (US)
- Nationwide Children's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- Cystic Fibrosis Foundation (US)
- University of Alabama at Birmingham (US)
- University of Minnesota Children's Hospital (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Clinical & Translational Endocrinology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1016/j.jcte.2025.100391
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52